Compare WKC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKC | MLYS |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1994 | 2023 |
| Metric | WKC | MLYS |
|---|---|---|
| Price | $37.29 | $15.84 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $37.00 | ★ $45.22 |
| AVG Volume (30 Days) | 709.9K | ★ 1.5M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $36,916,600,000.00 | N/A |
| Revenue This Year | $35.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.21 | $18.12 |
| 52 Week High | $41.20 | $47.65 |
| Indicator | WKC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 24.38 |
| Support Level | $34.97 | N/A |
| Resistance Level | $37.88 | $31.19 |
| Average True Range (ATR) | 0.96 | 1.35 |
| MACD | 0.10 | -0.23 |
| Stochastic Oscillator | 80.07 | 4.23 |
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.